Drug Type CAR-T |
Synonyms Anti-CD19-Car T cell therapy, PCAR 19B, pCAR-19B细胞自体回输制剂(Chongqing Precision Biotechnology) |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (CN), Breakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD19-positive B-cell acute lymphoblastic leukemia | NDA/BLA | CN | 20 Jul 2024 | |
CD19 Positive B-Cell Leukemia | Phase 2 | CN | 26 Jan 2022 | |
Refractory Adult Acute Lymphoblastic Leukemia | Phase 2 | CN | 26 Jan 2022 | |
Systemic Lupus Erythematosus | Phase 1 | CN | 04 Jan 2024 | |
CD19 positive Non-Hodgkin Lymphoma | Phase 1 | CN | 06 Sep 2021 | |
Non-Hodgkin's lymphoma refractory | Phase 1 | CN | 06 Sep 2021 | |
Recurrent Non-Hodgkin Lymphoma | Phase 1 | CN | 06 Sep 2021 |
NCT04888442 (ASH2022) Manual | Phase 1 | Pre B-cell acute lymphoblastic leukemia CD19 Positive | 9 | (autgsgymun) = uxbfcsnmrw ljvhmmqflk (uaiijjhbml ) View more | Positive | 15 Nov 2022 |